Technical Intelligence & Insights
Explore our curated collection of technical analyses and commercial scale-up strategies specifically focused on Salt Formation and Crystallization. These insights are designed to support R&D and procurement teams in optimizing their supply chains.
Patent CN107325013B reveals efficient synthesis route. Offers cost reduction and supply chain reliability for high-purity pharmaceutical intermediates manufacturing globally.
Patent CN118772067A reveals citrate salt crystallization for high-purity elagolix intermediates, offering cost reduction and scalable supply chain solutions.
Advanced purification method for Lesinurad intermediate achieving over 99% HPLC purity. Cost-effective salt formation technology for reliable pharmaceutical supply chains.
Patent CN1041933C reveals stable tertiary-tertiary diamine salts of clavulanic acid, offering superior crystallinity and purification efficiency for pharmaceutical manufacturing.
Patent CN112694445A reveals a high-purity purification method for Elagolix intermediates using L-tartaric acid, ensuring >99% purity for scalable API manufacturing.
Advanced purification patent CN121021353A enables high-purity ADC linker production with simplified crystallization processes for reliable pharmaceutical intermediate supply chains.
Patent CN102127021B details a novel solubilization method for bisbenzimidazole salts ensuring high purity and scalable manufacturing for global pharmaceutical supply chains.
Patent CN102001992A reveals a novel salt-recrystallization method for high-purity clevidipine butyrate, eliminating column chromatography for cost-effective manufacturing.
Novel salt recrystallization route for Telmisartan achieving >99.8% purity without high-boiling solvents. Ideal for reliable API supplier partnerships.
Patent CN102746289B reveals a robust crystallization process for Lurasidone Hydrochloride, ensuring high purity and low solvent residue for cost reduction in pharmaceutical manufacturing.
Advanced purification of Abiraterone acetate via oxalate salt formation. Eliminates column chromatography, ensures >99.5% purity, and offers scalable manufacturing solutions.
Patent CN104072477B details a high-purity imatinib refining method controlling genotoxic impurities. Offers supply chain stability and cost reduction in pharmaceutical intermediates manufacturing.
Novel crystalline cephamycin intermediate via salt formation. Enhances stability and purity for cefminox sodium production. Reliable supply chain solution.